4. Generation of Genetically Modified Mice and Rats through Use of Genome Editing Technology
Axcelead was one of the first in Japan to introduce the CRISPR/Cas 9 System which is capable of efficiently editing the genome. As such, in only about 3 months we are able to provide homozygous knockout animals lacking the target gene, which is only a third of the time (approximately 3 months) usually required. For Knock-in animal production we provide homozygous Knock-in mice and rats ranging from several bps to more than a dozen kbps in a short period of time (approximately 9 months).
5. Additional Genome Editing to Severely Immunodeficient Mice
Axcelead has an original severely immunodeficient mouse model, the NOD/Scid-Il2rg KO mouse, which supports regenerative medicine tests, including cell transplantation thanks to its excellent engraftment properties for human cells. By using genome editing technology, we are able to introduce additional genetic modification into the severely immunodeficient mouse. Furthermore, since Axcelead utilizes an in-house severely immunodeficient mouse, it is possible for you to quickly start your planned trials.
6. Immunosuppressed large animal models for Long-term Efficacy & Safety Studiess
Tailor-made immunosuppressed pig models are created by removing immune organs (thymus and spleen) and treating the animals with immunosuppressants while monitoring the pharmacokinetics profile.
Immunosuppressed monkey models are created by the administration of immunosuppressants only.
Once a pathological condition such as heart failure and T1D diabetes is developed in the immunosuppressed large animal models, it is then possible to conduct efficacy and safety studies of human-derived regenerative medical products. Long-term efficacy and safety studies using large animal models, previously not possible, are now possible in pigs which are closer in body and organ size to humans than small animals.
Go to the Introductory page of Pharmacological studies using immunosuppressed pig models
■ Tailor-Made Immunosuppressive Pig and Monkey Models
The target blood concentration level of the immunosuppressant in vivo was calculated by the results of the in vitro peripheral blood mononuclear cells proliferation studies. The pharmacokinetic studies are conducted to confirm that the in vivo plasma concentration reach the target concentration.
Only Axcelead offers tailor-made tests.